The makers of the cholesterol-lowering drugs Crestor, Tricor, and ABT-335 are collaborating on a new cholesterol treatment that will target all three major blood lipids, including both "good" and "bad" cholesterol. The companies, AstraZeneca and Abbott Laboratories, will share costs of development of the drug and hope to submit a regulatory application for the combination therapy in 2009.
Read moreThe JUPITER study has been the subject of countless headlines reporting the unprecedented reduction in heart attacks with the cholesterol... Read more »
A recent study has shown that a combination of Crestor and Zetia (ezetimibe) helps high-risk patients lower their cholesterol levels better than... Read more »
According to new research, the combination drug Vytorin is more effective at lowering bad cholesterol than Crestor. Vytorin works on two sources of... Read more »
A new study has found that patients who take a combination of the cholesterol drugs TriLipix and Crestor improve their heart risk factors more than... Read more »
Researchers have found that a combination of Crestor and Zetia cut bad cholesterol by 70 percent in a recent study. According to one researcher, the... Read more »
Researchers at the Methodist DeBakey Heart Center have found that a combination of Crestor (rosuvastatin) and Zetia (ezetimibe) reduces both LDL... Read more »